Under the agreement, both institutions will share information and data to ensure effective oversight of drug prices, availability, and marketing practices.
-
Web Desk
-
KARACHI: The Competition Commission of Pakistan (CCP) and the Drug Regulatory Authority of Pakistan (DRAP) have signed a Memorandum of Understanding (MoU) to enhance cooperation in monitoring the pharmaceutical market.
Under the agreement, both institutions will share information and data to ensure effective oversight of drug prices, availability, and marketing practices.
The MoU outlines collaboration in the following areas: establishing a framework for effective monitoring of drug prices and availability, reviewing misleading advertisements of pharmaceutical products and conducting joint monitoring of cartelization within the pharmaceutical market.
Beside this, enhancing policy research, data sharing, and institutional capacity, cooperating to prevent misleading online marketing of medicines and taking joint measures to ensure the availability of essential drugs.
Sultan Amin, Member of CCP, emphasized the importance of collaboration to curb deceptive online marketing, while Dr. Ubaidullah, CEO of DRAP, highlighted the need for joint efforts to ensure the availability of essential medicines.
